5 Key Takeaways

• 1

  CDMOs are essential for pharmaceutical innovation, providing expertise and capacity when internal resources are insufficient.

• 2

  Traditional CDMO models face challenges due to geopolitical volatility, regulatory changes, and the complexity of drug development.

• 3

  Large pharma companies are shifting towards strategic partnerships with CDMOs, focusing on long-term collaboration rather than price-based contracts.

• 4

  The Extended Bench model allows CDMOs to offer flexible resources and leverage global networks to meet evolving project needs.

• 5

  Smaller companies benefit from CDMOs' capabilities to accelerate timelines and streamline processes from development to manufacturing.